Citadel Advisors
IBO

Citadel Advisors’s Impact BioMedical IBO Stock Holding History

Citadel Advisors’s Portfolio IBO Stock Details IBO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$22.8K Buy
+49,567
New +$29.3K ﹤0.01% 13376
2025
Q2 		– Sell
-60,315
Closed -$52.5K – 15612
2025
Q1 		$52.5K Buy
+60,315
New +$104K ﹤0.01% 12268

Other funds holding IBO

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Vanguard Global Advisers
Vanguard Global Advisers Malvern, Pennsylvania $215B AUM
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
MAC
Mason & Associates (California) Los Angeles, California $619M AUM 29.44% 1-Year Est. Return

Citadel Advisors's IBO Position: Q2 2026 in Review

Citadel Advisors opened a new position in Impact BioMedical (IBO) in Q2 2026: 49,567 shares worth $22.8K. The stake represents ﹤0.01% of the portfolio and ranks #13376 among its holdings. This is a return to the name: Citadel Advisors previously reported a position in IBO as recently as Q1 2025.

Citadel Advisors first reported a position in IBO in Q1 2025 and has held it in 2 quarters since. The position peaked at $52.5K in Q1 2025. 22 funds tracked by Wall St. Rank hold IBO as of Q2 2026.

  • Citadel Advisors held 49,567 shares of Impact BioMedical worth $22.8K as of Q2 2026.
  • Impact BioMedical was a new Citadel Advisors position in Q2 2026.
  • Impact BioMedical made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #13376 holding.
  • Citadel Advisors first reported a position in Impact BioMedical in Q1 2025 and has held it in 2 quarters since.
  • Citadel Advisors's Impact BioMedical position peaked at $52.5K in Q1 2025.
  • 22 funds tracked by Wall St. Rank held Impact BioMedical as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.